Lipigesic

SCHOFIELD, Wis., April 24, 2012 /PRNewswire/ – PuraMed BioScience, Inc. ® (OTC Bulletin Board: PMBS), the producer of over-the-counter medicinal and healthcare products, has implemented an aggressive public awareness campaign to promote LipiGesic M in the retail sector with major campaigns planned in May and June to promote sales at both Walgreens and CVS/pharmacy stores. [...]

“When you patrol the micro-cap market niche you will every so often feel a thrill if you think you have found a fabulous winner early,” said Bob Flaherty, financial news editor, in his recent newsletter, recommending PuraMed BioScience, Inc.®, as a company with a solid product offering and a bright future. “It’s an honor  to write [...]

SCHOFIELD, Wis., Feb.15, 2012 /PRNewswire/ – PuraMed BioScience®, Inc. (OTC Bulletin Board: PMBS), the producer of over-the-counter medicinal and healthcare products, announced today its financial results for the second quarter ended December 31, 2011 in conjunction with the publication of its quarterly 10Q SEC filing. PuraMed BioScience reported net revenues for the three months ended December [...]

Schofield, Wis., February 7, 2012 – PuraMed BioScience, Inc. (OTC QB: PMBS) announced today that it has recently commenced a clinical study of its unique non –prescription migraine treatment, LipiGesic®M on children and adolescents.  Currently there are no prescription migraine medications recommended for those under the age of 18, and PuraMed hopes to attract that [...]

SCHOFIELD, Wis., Jan. 25, 2012 /PRNewswire/ — PuraMed BioScience, Inc. (OTCBB: PMBS.OB – News) announced today that LipiGesic M, their clinically proven effective and safe, all natural product for the treatment of migraine headaches, is now available for purchase at CVS, the 2nd Largest Drug Chain in the United States. With the addition of over [...]

SCHOFIELD, Wis. , Dec. 28, 2011 /PRNewswire/ — PuraMed BioScience, Inc. (OTCBB: PMBS.OB – News) is pleased to announce that its lead product, LipiGesic®M, for the acute treatment of migraines, has been featured in the December 20, 2011 issue of Flaherty Financial News Newsletter published by Flaherty  Financial News Inc.  The report can be found [...]

SCHOFIELD, Wis., Dec. 21, 2011 — PuraMed BioScience, Inc., (OTCBB: PMBS.OB) announced today, an outline of its plans for the national product launch of its clinically tested migraine treatment LipiGesic® M. The Company has always emphasized science as the key to their success and this year three of the top headache researchers in the United [...]

SCHOFIELD, Wis., December, 2011 – PuraMed BioScience Inc., (OTCBB: PMBS) is pleased to announce the appointment of Charles A. Phillips to the Board of Directors. Phillips began his pharmaceutical career in 1989 when he helped create, via an IPO, The Quigley Corporation; Phillips was COO and Board memeber until the company’s take over in 2009. [...]

SCHOFIELD, Wis., Dec. 6, 2011 (GLOBE NEWSWIRE) — PuraMed BioScience Inc. (OTCBB:PMBS) announced today that it has received an initial series of purchase orders for its new over-the-counter migraine medication, LipiGesic®M with the second largest chain drug retailer in the United States, CVS. This follows a recent announcement that LipiGesic M is now available nationwide [...]

SCHOFIELD, Wis., Nov. 28, 2011 (GLOBE NEWSWIRE) — PuraMed BioScience, Inc. (OTCBB:PMBS) announced today that their new non-prescription migraine medication, LipiGesic®M, is now available for sale nationwide at the number one chain of drugstores in the United States, Walgreens. Walgreens, with its over 7,700 locations is the nation’s largest drugstore chain and is the only [...]